ODX Formulations for Drug Delivery and Other Approaches to Overcome Swallowing Problems

Dear colleagues,

Orodispersible drug delivery systems (ODx) have received a considerable amount of interest in recent years due to their suitability for patients suffering from dysphagia. These patients have difficulty swallowing common oral formulations, such as tablets and capsules, and as such, ODx present a much more acceptable alternative for them.

ODx rapidly disintegrate after placement in the oral cavity. The active pharmaceutical ingredients are swallowed with the saliva and/or are absorbed via the oral mucosa. They comprise orodispersible films (ODF), orodispersible (mini)tablets (OD(M)T), lyophilisates, and granules. The various ODx formulations currently available can be used for the treatment of local and systemic disorders and vaccination. ODX formulations can be prepared on a small as well as (semi-)industrial scale using different manufacturing techniques (e.g., solvent casting technique, various printing techniques).

This Special Issue aims to highlight the current research activities in the areas of formulations intended to be used in the oral cavity. Authors are invited to submit original work and review articles covering all aspects of ODx formulation development and other approaches to overcome swallowing problems.

Publications on mucoadhesive buccal drug delivery systems (MBx), such as mucoadhesive buccal films and tablets, may also be included.

Dr. J. Carolina Visser
Dr. Herman Woerdenbag
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.